TABLE 3

Agreement Measurements by Type of Intended Therapy at 60 Days After PET

		PPV		Raw agreement		Kappa
Post-PET planned therapy and cancer type	NOPR plan (n)	%	95% confidence interval	%	95% confidence interval	κ	95% confidence interval
Any systemic therapy
All	3,030	79.3	77.9–80.8	74.1	72.7–75.4	0.40	0.37–0.43
Bladder	676	79.0	75.9–82.1	73.0	75.6–79.0	0.42	0.36–0.48
Ovarian	223	86.1	81.6–90.6	82.5	78.1–86.9	0.52	0.41–0.64
Pancreatic	854	79.3	76.6–82.0	72.8	70.3–75.4	0.33	0.27–0.39
SCL	629	89.5	87.1–91.9	83.8	81.2–86.5	0.34	0.24–0.43
Stomach	648	67.6	64.0–71.2	67.6	64.8–70.4	0.34	0.29–0.40
Any radiation
All	1,293	64.7	62.1–67.3	80.8	79.6–82.0	0.53	0.51–0.56
Bladder	337	68.8	63.9–73.8	83.3	81.1–85.5	0.60	0.55–0.65
Ovarian	23	30.4	11.6–49.2	91.6	88.4–94.8	0.32	0.12–0.53
Pancreatic	362	70.2	65.5–74.9	82.8	80.6–84.9	0.59	0.54–0.64
SCL	321	69.2	64.1–74.2	72.5	69.3–75.8	0.44	0.38–0.51
Stomach	250	48.8	42.6–55.0	79.0	76.5–81.4	0.39	0.32–0.45
Any surgery
All	1,031	63.6	60.7–66.6	77.9	76.7–79.2	0.43	0.40–0.46
Bladder	248	56.9	50.7–63.0	75.8	73.2–78.3	0.36	0.30–0.42
Ovarian	57	52.6	39.7–65.6	75.9	69.6–79.3	0.31	0.19–0.44
Pancreatic	242	59.9	53.7–66.1	77.8	74.1–78.8	0.39	0.33–0.45
SCL	26	50.0	30.8–69.2	85.4	82.6–87.7	0.15	0.06–0.24
Stomach	458	71.4	67.3–75.5	75.7	70.3–75.4	0.50	0.45–0.56